

28 June - 4 July

COMPANY SPOTLIGHT

- **miRagen Therapeutics, Inc.** (Boulder) and **Santaris Pharma A/S** (San Diego, CA) announced that they have formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease. miRagen is planning to develop and commercialize single-stranded LNA-based product candidates intended for the treatment of cardiovascular disease by utilizing Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform. Under the terms of the agreement, Santaris Pharma A/S received a minority equity interest in miRagen, and is eligible to receive milestone payments and royalties upon achievement of certain development and regulatory milestones.
- **Cerapedics, Inc.** (Westminster) announced that it received the CE Mark for its i-FACTOR™ Flex bone graft product line. i-FACTOR Flex is the company's second product in the i-FACTOR product platform based on its proprietary small peptide attachment factor technology. i-FACTOR bone graft is the only biologic bone graft that combines a unique anorganic bone mineral (ABM) and small peptide (P-15™) to act as an attachment factor for specific integrins on osteogenic cells. The company's first product, i-Factor Putty bone graft, received a CE mark in 2008 and is currently being evaluated in the United States (FDA) as part of an Investigational Device Exemption (IDE) Clinical Study in spine.
- **nSpire Health** (Longmont) announced a three-year contract with Amerinet Group Purchasing Organization. The agreement offers Amerinet customer hospitals and clinics exclusive access to nSpire Health's broad range of respiratory products and services, including the newly released HDpft™ pulmonary function testing systems through June 30, 2013.
- **Aeolus Pharmaceuticals, Inc.** (Mission Viejo, CA) reported that researchers from **National Jewish Health and the University of Colorado Anschutz Medical Campus** have completed studies demonstrating that AEOL 10150 provides statistically significant protection of the skin in the 2-chloroethyl-ethylsulfide (CEES; half mustard) model of mustard gas exposure in mice and in a human cell culture model. There are currently no effective treatments for mustard gas exposure and AEOL 10150 is a major focus of a sponsored research grant awarded by the NIH Counteract program to National Jewish Health to identify an effective treatment.
- **Novus Biologicals, LLC** executed an exclusive distribution agreement with Boulder-based startup, **AmideBio, LLC** to distribute their line of peptides to bioscience researchers worldwide. AmideBio develops and manufactures peptides based on IP licensed from the University of Colorado. The inventor of

this line of peptides is Dr. Michael Stowell, CU/MCDB, who is also the Chief Technology Officer for AmideBio. Dr. Stowell's new manufacturing technique has the potential both to reduce costs and to make it feasible to manufacture drugs that were previously difficult to produce with conventional methods.

SQUARE PEGS

- Holli Baumunk, Vice President of the **Metro Denver Economic Development Corporation** for the past seven years, has been named President & CEO of the **Colorado BioScience Association (CBSA)**, effective July 12. The announcement is made by Rick Jory, CBSA Board Chairperson, who says Baumunk was unanimously recommended to the board for approval by the CBSA Executive Search Committee, a subcommittee of the board formed earlier this year. Denise Brown, CBSA's Founding Executive Director and recently named board member, has been serving as Interim Executive Director of the trade association during the search process.
- **The Coloradoans for Responsible Reform** campaign has launched a "[Don't Hurt Colorado](#)" website to defeat Amendment 60, Amendment 61, and Proposition 101.
- **Griff/SMC** (Boulder), one of the nation's leading medical marketing communications firms and the oldest full-service advertising agency in Boulder, Colorado, is celebrating its 35th year in business. To commemorate this summer's milestone anniversary, the agency has crafted a new website, www.griffsmc.com.

UPCOMING EVENTS

- BioMARC, the regional training center for product translation at Colorado State University, will be holding a workshop on July 22-23 on Clinical Trials, FDA Requirements, and GCP. [Click here for more information \(PDF\)](#).
- The July Innovation After Hours will feature Nanopartz, which is the City of Loveland's newest BioScience company. The event will take place on July 8th at 4 pm at the Loveland Art Lab. Registration details for the free event are available [here](#).
- On Monday July 12, from noon to 5pm, Congresswoman Betsy Markey will hold an Innovation Summit. The event will be held in conjunction with the City of Fort Collins and Colorado State University. The keynote speaker will be John R. Fernandez, the Assistant Secretary for Economic Development and the U.S. Department of Commerce. The meeting will take place in the Main Ballroom of the Lory Student Center, with networking at Odell Brewing Company immediately following. The event is free but RSVP is required. Please respond to Jamie Grim at jamie.grim@mail.house.gov or 970-221-7110.

- An informal meeting to discuss Bioscience Education will be held on July 14 from 1:30 to 3:30 pm in the Amgen Room of the Bioscience Center at Fitzsimons. The aims of the meeting are information sharing, programmatic awareness, and discussing collaborative planning for resource sharing, fund raising, and potentials for development of industry linkages and multipurpose training sites. Please RSVP to Jerry McCarthy at fairhill@gmail.com or call 303-229-0957.

- Colorado State University's BioMARC Outreach Training Program for Product Translation will host a workshops on Clinical Trial Management, FDA Requirements, & GCP in the Amgen Conference Room Bioscience Park Center at Fitzsimons on [July 22](#) and [July 23](#). The second session on July 23 will focus on medical devices.

- The next CBSA BioBreakfast will be held on July 28th on the Anshutz Medical Campus. Each year the CBSA dedicates one BioBreakfast to spotlighting an article within the annual Bioscience Colorado Magazine. This year's program is one you can't afford to miss. Listen as Dr. Larry Gold, Dr. Bill Freytag and Patrick Mahaffy explain what propelled them to grow successful bioscience companies and become leaders of the industry. More information and registration details can be found [here](#).

- The Frontiers of Science Institute is holding its 1st Annual "Mad Scientist Golf Tournament" on August 13 at Eaton Country Club. FSI is a 6-week, summer, residential STEM (Science, Technology, Engineering, Mathematics) immersion program at UNC for motivated Colorado high school juniors and seniors – all proceeds will benefit FSI. Details on the tournament are on the attached flyer.

SAVE THE DATE: Please join us for the **Roche Colorado Corporation** Peptide Symposium (RCCPS) on September 14 – 16, 2010 at the St. Julien Hotel and Spa in Boulder, CO. The program highlights include; Peptides in the Clinic; Peptide Drug Delivery; Emerging Technologies; Advances in Peptide Chemistry; and, Quality by Design in Peptides. The following link www.rccps.org, and attachments will provide additional information on the conference and sponsorship opportunities. We look forward to showcasing Colorado as a leader in Peptides at this conference and hope you will be able to join us! Please see attached flyer for information on sponsorship opportunities.